Premium
Complete remission seven years after treatment for metastatic malignant melanoma
Author(s) -
Petit Thierry,
Borel Christian,
Rixe Olivier,
Avril MarieFrancoise,
Monnier Alain,
Giroux Bruno,
Weil Marise,
Khayat David
Publication year - 1996
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19960301)77:5<900::aid-cncr14>3.0.co;2-7
Subject(s) - medicine , melanoma , metastatic melanoma , complete remission , chemotherapy , surgery , complete response , progressive disease , phases of clinical research , cancer , oncology , cancer research
BACKGROUND In this study, the authors identified seven‐year survivors after completion of the French multicenter Phase II trial of fotemustine for the treatment of metastatic malignant melanoma. METHODS One hundred sixty‐nine patients with metastatic malignant melanoma were included in this Phase II study. One hundred fifty‐three patient records were evaluable with an overall response rate of 24.2%. RESULTS Five of these patients are alive and in complete remission. One patient had a complete response after fotemustine administration and then relapsed. One patient had a partial response. Three patients had stable disease. These five patients underwent surgery for relapse or residual disease and subsequently achieved durable complete remission. CONCLUSIONS Long term survival may be the outcome after surgical resection of residual metastatic melanoma after chemotherapy. Cancer 1996;77:900‐2.